This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Choussat, R.e. Articles by Thomas, D. Search for Related Content PubMed PubMed Citation Articles by Choussat, R.e. Articles by Thomas, D.

A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention

R.émi Choussat, MD^*, Gilles Montalescot, MD, PhD^*,*, Jean Philippe Collet, MD, PhD^*, Eric Vicaut, MD, PhD, Annick Ankri, MD, Vanessa Gallois, BSc^*, G.érard Drobinski, MD, PhD^*, Ivan Sotirov, MD^* and Daniel Thomas, MD^*

^* Department of Cardiology, Paris, France
Hemostasis Laboratory, Pitié-Salpêtrière Hospital, Paris, France
Laboratory of Biophysics, Fernand-Widal Hospital, Paris, France

View larger version (12K): [in a new window]   Figure 1 Distribution of anti-Xa activity levels at the beginning (A) and end (B) of percutaneous coronary intervention.

View larger version (10K): [in a new window]   Figure 2 Anti-Xa activity levels before, during, and after percutaneous coronary intervention (PCI), with the use (open circles) and nonuse (closed circles) of eptifibatide.